164


PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number Application Numb r 09/820.003 TRANSMITTAL Filing Date March 29, 2001 **FORM** First Named Inventor MERKULOV et al. Art Unit 1642 (to be used for all correspondence after initial filing) **Examiner Name** Rawlings **Attorney Docket Number** CL001196 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Fee Transmittal Form Drawing(s) to a Technology Appeal Commun Licensing-related Papers of Appeals and I Fee Attached Appeal Commun ~ (Appeal Notice, B Amendment/Reply Petition to Convert to a Proprietary Infon After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure **Terminal Disclaimer Extension of Time Request** Identify below): Substitute Seq. Listin Request for Refund **Express Abandonment Request** diskette. CD, Number of CD(s) Information Disclosure Statement Remarks Certified Copy of Priority Document(s) Add'l Other: Copy of Notice to Comply Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Justin D. Kariala, Reg. No.: 43, 704 Individual Signature Date July 18, 2003 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: Typed or printed

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Signature

Date

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



## **Notice to Comply**

Application No. Applicant(s) 09/820,003 MERKULOV ET AL. Examiner Art Unit 1642 Stephen L. Rawlings, Ph.D.

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

(	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is exted to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, and 1211 OG 82 (June 23, 1998).	
	his application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as irred by 37 C.F.R. 1.821(c).	
	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by C.F.R. 1.821(e).	
_ (	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the omputer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the ttached copy of the marked -up "Raw Sequence Listing."	
Į	The computer readable form that has been filed with this application has been found to be damaged and/or nreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be ubmitted as required by 37 C.F.R. 1.825(d).	
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other: There remains the disclosure of the amino acid sequence, "DTAGQ" at page 3, which is not properly identified by a sequence identification number. If necessary, Applicants are required to submit substitute copies of the sequence listing, as indicated below.		
Applicant Must Provide:  ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
☑ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.		
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
For	questions regarding compliance to these requirements, please contact:	RECEIVED
	Rules Interpretation, call (703) 308-4216	JUL 2 2 2003
_	0.000 0	JUL " " LOSO

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

U.S. Patent and Trademark Office

Technical Assistance......703-287-0200 To Purchase Patentln Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Part of Paper No. 11

TECH CENTER 1600/2900